| Cat.No. | Name | Information |
|---|---|---|
| M1672 | BI 2536 | BI 2536 is a novel, highly selective, potent dual PLK1 and BRD4 inhibitor with IC50s of 0.83 and 25 nM, respectively. |
| M49490 | 3MB-PP1 | 3MB-PP1 is a bulky purine analog and inhibitor of Polo-like kinase 1 (Plk1) that blocks mitotic progression and cytokinesis by targeting Plk1 in cells expressing the analog-sensitive Plk1 allele. 3MB-PP1 also specifically inhibits the activity of Leu93 mutant Zipper-interacting Ssn3 (Cdk8). 3MB-PP1 inhibits the activity of Leu93 mutant Zipper-interacting Ssn3 (Cdk8). In addition, 3MB-PP1 specifically inhibits the activity of analog-sensitive Ssn3 (Cdk8). 3MB-PP1 inhibits the Leu93 mutant Zipper-interacting protein kinase (Leu93-ZIPK; IC50=2 μM). 3MB-PP1 can be used in the mycelium of Candida albicans. 3MB-PP1 can be used in studies related to mycelium formation and cell division in Candida albicans. |
| M31203 | ON1231320 | ON1231320 is a highly specific polo like kinase 2 (PLK2) inhibitor with an IC50 of 0.31 µM. ON1231320 blocks tumor cell cycle progression in the G2/M phase in mitosis, causing apoptotic cell death. |
| M20605 | CFI-400945 | CFI-400945 is an orally active, potent and selective polo-like kinase 4(PLK4) inhibitor with Ki value of 0.26 nM. |
| M13719 | Rigosertib (free base) | Rigosertib (ON-01910) is a multi-kinase inhibitor and a selective anti-cancer agent, which induces apoptosis by inhibition the PI3 kinase/Akt pathway, promots the phosphorylation of histone H2AX and induces G2/M arrest in cell cycle. |
| M13718 | Onvansertib | Onvansertib (PCM-075, NMS-1286937, NMS-P937) is a first-in-class, third-generation, oral, highly selective PLK1 inhibitor that induces tumor cell arrest in the G2/M phase and triggers apoptosis. It has a median IC50=136nM against a variety of CRC cell lines and inhibits xenograft models such as HT-29, HCT-116, and Colo-205 well. |
| M9307 | TC-S 7005 | TC-S 7005 is a potent and selective polo-like kinase 2 (PLK2) inhibitor (IC50 = 4 nM). |
| M9250 | HMN-176 | HMN-176 inhibits mitosis, interfering with polo-like kinase-1 (plk1), without significant effect on tubulin polymerization. |
| M8519 | Mps1-IN-2 | Mps1-IN-2 is a potent and selective inhibitor of Mps1 kinase. |
| M7271 | SBE13 hydrochloride | SBE13 hydrochloride is a potent and selective PLK1 inhibitor. |
| M6576 | Centrinone | Centrinone is a high affinity and selective PLK4 inhibitor. |
| M3293 | HMN-214 | HMN-214 is a procompound of HMN-176, which alters the cellular spatial orientation of Plk1. |
| M3198 | TAK-960 | TAK-960 is a novel, potent and selective Plk1 inhibitor with IC50 of 8 nM. |
| M2983 | Ro3280 | RO3280 is a potent, highly selective inhibitor of Polo-like kinase 1 (PLK1) with IC50 of 3 nM. |
| M2860 | MLN0905 | MLN0905 is an orally active, potent PLK1 inhibitor with an IC50 of 2 nM. can be used in tumor related studies. |
| M2741 | GW843682X | GW 843682X is a PLK inhibitor for PLK1 and PLK3 with IC50 of 2.2 nM and 9.1 nM, respectively. |
| M2211 | Rigosertib sodium | Rigosertib sodium is a dual non-ATP inhibitor of polo-like kinase 1 (Plk1) and phosphoinositide 3-kinase pathways (PI3K). |
| M1719 | GSK461364 | GSK461364 is a potent and selective small molecule inhibitor of Polo-like kinase 1 (PLK1) with a Ki of 2.2 nM. |
| M1678 | BI 6727 | BI 6727 (Volasertib) is a small highly potent Polo-like kinase inhibitor (Plk1) with an IC50 of 0 .87 nM. |
| M56017 | (1E)-CFI-400437 dihydrochloride | (1E)-CFI-400437 dihydrochloride is a potent PLK4 (IC50= 0.6 nM) inhibitor and selective against other members of the PLK family (>10 μM). |
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2024 AbMole BioScience. All Rights Reserved.
